1.
Ann Clin Microbiol Antimicrob
; 13: 13, 2014 Apr 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24708819
RESUMO
BACKGROUND: Due to the emergency of multidrug-resistant strains of Mycobacterium tuberculosis, is necessary the evaluation of new compounds. FINDINGS: Tedizolid, a novel oxazolidinone, and ACH-702, a new isothiazoloquinolone, were tested against M. tuberculosis infected THP-1 macrophages. These two compounds significantly decreased the number of intracellular mycobacteria at 0.25X, 1X, 4X and 16X the MIC value. The drugs were tested either in nanoparticules or in free solution. CONCLUSION: Tedizolid and ACH-702 have a good intracellular killing activity comparable to that of rifampin or moxifloxacin.
Assuntos
Antituberculosos/farmacologia , Macrófagos/microbiologia , Mycobacterium tuberculosis/efeitos dos fármacos , Organofosfatos/farmacologia , Oxazóis/farmacologia , Quinolonas/farmacologia , Tiazóis/farmacologia , Carga Bacteriana , Linhagem Celular , Humanos , Mycobacterium tuberculosis/crescimento & desenvolvimento
2.
Salud Publica Mex
; 60(6): 738, 2018.
Artigo
em Espanhol
| MEDLINE
| ID: mdl-30699279